References

1. Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, Umstead BR, Mays MC, Lee JS. (2019) Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med, 380 (19): 1825-1833. [PMID:30883047]

2. Buchanan A, Newton P, Pehrsson S, Inghardt T, Antonsson T, Svensson P, Sjögren T, Öster L, Janefeldt A, Sandinge AS et al.. (2015) Structural and functional characterization of a specific antidote for ticagrelor. Blood, 125 (22): 3484-90. [PMID:25788700]

3. Cave B, Rawal A, Ardeshna D, Ibebuogu UN, Sai-Sudhakar CB, Khouzam RN. (2019) Targeting ticagrelor: a novel therapy for emergency reversal. Ann Transl Med, 7 (17): 410. [PMID:31660309]

4. Ortega-Paz L, Giordano S, Franchi F, Rollini F, Pollack Jr CV, Bhatt DL, Angiolillo DJ. (2023) Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab. Clin Pharmacokinet, 62 (5): 673-692. [PMID:37118383]